A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease (TargetTau-1)
A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease (TargetTau-1)
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Inclusion Criteria
Exclusion Criteria
Griffith University, Queensland 4222, Australia
Antwerpen, Brussels Capital 2018, Belgium
Toride-Shi, Ibaraki 302-0004, Japan
Kurashiki-Shi, Okayama-ken 710-0813, Japan
Hirakata-Shi, Osaka 573-1121, Japan
Bunkyo-Ku, Tokyo 1130034, Japan
Hachioji-Shi, Tokyo 192-0071, Japan
Setagaya-Ku, Tokyo 1588531, Japan
Himeji-shi, 670-8560, Japan
Kasukabe-Shi, 344-0036, Japan
Kodaira-Shi, 187-8551, Japan
Musashimurayama-Shi, 208-0022, Japan
Musashino-shi, 180-8610, Japan
Tachikawa-Shi, 190-0022, Japan
Takatsuki-Shi, 569-1192, Japan
Toyonaka-Shi, 560-0004, Japan
Songpa-gu, Seoul 138-736, South Korea
Gwangjingu, 143-729, South Korea